Clinical data | |
---|---|
Other names | Methyldiazirinol; 3,3-Azo-17α-methyl-5α-dihydrotestosterone; 3,3-Azo-17α-methyl-DHT; 3,3-Azo-17α-methyl-5α-androstan-17β-ol; 3-Azi-17α-methyl-5α-androstan-17β-ol |
Routes of administration | By mouth |
Drug class | Androgen; Anabolic steroid |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H32N2O |
Molar mass | 316.489 g·mol−1 |
3D model (JSmol) | |
| |
|
Methyldiazinol (also known as 3,3-azo-17α-methyl-5α-dihydrotestosterone, 3-azi-17α-methyl-DHT, or 3,3-azo-17α-methyl-5α-androstan-17β-ol) is a synthetic and orally active androgen/anabolic steroid (AAS) which was never marketed.[1][2] It is a 17α-methylated derivative of dihydrotestosterone (DHT); specifically, it is the C3 azi (i.e., 3,3-azo) analogue of mestanolone (17α-methyl-DHT).[1][2] The drug has been found to possess a high ratio and dissociation of myotrophic to androgenic activity; relative to methyltestosterone, its ratio was 15 (3:0.2), among the highest observed.[1][2]
Methyldiazinol: 3-Azi-17-methyl-5α-androstan-17β-ol: The 3-azi derivative of methandrostanolone was noted by CHURCH et al. (1965) to have a wide myotrophic:androgenic dissociation (3: 0.2) 15 relative to methyltestosterone orally, among the highest noted.